Quarterly ResultMay 5, 2026, 09:07 AM
Nuvectis Pharma Q1 Net Loss $(6.05)M; Cash $25.1M
AI Summary
Nuvectis Pharma reported a net loss of $(6.05) million for the first quarter ended March 31, 2026, an increase from $(5.33) million in the prior year. Cash and cash equivalents decreased to $25.1 million from $31.6 million at the end of 2025, with net cash used in operating activities rising to $(6.51) million. The company continues to advance its NXP900 clinical program, initiating the Phase 1b combination study in December 2025, but acknowledges the need for substantial additional capital to fund future operations and clinical trials.
Key Highlights
- Net loss increased to $(6.05) million for Q1 2026 from $(5.33) million in Q1 2025.
- Cash and cash equivalents decreased to $25.1 million as of March 31, 2026.
- Net cash used in operating activities was $(6.51) million in Q1 2026.
- Research and development expenses rose to $4.11 million in Q1 2026.
- General and administrative expenses increased to $2.15 million in Q1 2026.
- Accumulated deficit reached $105.7 million as of March 31, 2026.
- Phase 1b combination study for NXP900 initiated in December 2025.
- $60.0 million remains available under the At-the-Market (ATM) Program.
Price Impact
More from NVCT